Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects.
Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects.
复制标题
DOI：
10.1016/j.msard.2020.102538
复制
发表时间：
2020-11
影响因子：
4
通讯作者：
Brod SA
中科院分区：
文献类型：
--
作者：
Brod SA
视神经脊髓炎（NMO -包括NMO谱系障碍[NMOSD]）是一种毁灭性的疾病。直到最近，还没有被证实的药物可以预防复发。我们现在有三种药物用于治疗NMO。我们可能建议以下顺序-第一行使用eculizumab快速有效和稳定，不影响获得性免疫系统，然后使用satrilizumab（长期免疫调节）。为突破性疾病保留免疫抑制剂，挽救重症AHSCBMT患者。在NMO中，控制补体，向调制过渡，抑制储备-并用AHSCBMT挽救严重的。视神经脊髓炎（NMO -包括NMO谱系障碍[NMOSD]）是一种毁灭性的疾病。83%的横髓鞘性（TM）发作患者和67%的视神经炎（ON）发作患者没有或部分恢复。直到最近，还没有被证实的药物可以预防复发。神经免疫学界缺乏针对NMOSD的适应症药物。我们现在有三种药物用于治疗NMO，包括eculizumab [Soliris®]，一种抗c5补体抑制剂，satalizumab （ENSRYNG®），一种针对IL-6受体（IL-6R）的单克隆抗体，可阻断B细胞抗体的产生，以及inebilizumab （Uplinza®），一种与B细胞表面抗原CD19结合的单克隆抗体，随后B和浆母细胞淋巴细胞溶解，抗体产生减少。自体造血干细胞骨髓移植（AHSCBMT）也被使用。在了解疾病的急性和严重程度、个体作用机制（MOA）和起效速度、起效期和长期安全性的情况下，我们如何对NMO治疗进行排序？我们可能建议以下顺序-第一行使用eculizumab快速有效和稳定，不影响获得性免疫系统，然后使用satrilizumab（长期免疫调节）。为突破性疾病保留免疫抑制剂，挽救重症AHSCBMT患者。在NMO中，控制补体，向调制过渡，抑制储备-并用AHSCBMT挽救严重的。
Neuromyelitis optica (NMO - including NMO spectrum disorders [NMOSD]) is a devastating disease. Up until recently, there was no proven agent to treat to prevent relapses. We now have three agents indicated for the treatment of NMO. We might suggest the following sequence – 1st line using eculizumab for rapid efficacy and stabilization without effect on the acquired immune system followed by satrilizumab (long term immunomodulation). Reserve inebilizumab (immunosuppressant) for breakthrough disease and salvage the severe with AHSCBMT. In NMO, control the complement, transition to modulation, and reserve suppression – and salvage the severe with AHSCBMT. Neuromyelitis optica (NMO - including NMO spectrum disorders [NMOSD]) is a devastating disease. Eighty-three percent of patients with transverse myelitic (TM) attacks and 67% of patients with optic neuritis (ON) attacks have no or a partial recovery. Up until recently, there was no proven agent to treat to prevent relapses. The neuro-immunological community had a dearth of indicated agents for NMOSD. We now have three agents indicated for the treatment of NMO including (eculizumab [Soliris®]), an anti-C5 complement inhibitor, satralizumab (ENSRYNG®), a monoclonal antibody against the IL-6 receptor (IL-6R) that blocks B cell antibody production and inebilizumab (Uplinza®), a monoclonal antibody that binds to the B-cell surface antigen CD19 with subsequent B and plasmablast cell lymphocytolysis with decreasing antibody production. Autologous hematopoietic stem cell bone marrow transplantation (AHSCBMT) has also been used. How do we sequence NMO therapies with the understanding of the acuteness and severity of the disease, the individual mechanism of action (MOA) and rapidity of onset of action, onset of efficacy and long-term safety of each agent? We might suggest the following sequence – 1st line using eculizumab for rapid efficacy and stabilization without effect on the acquired immune system followed by satrilizumab (long term immunomodulation). Reserve inebilizumab (immunosuppressant) for breakthrough disease and salvage the severe with AHSCBMT. In NMO, control the complement, transition to modulation, and reserve suppression – and salvage the severe with AHSCBMT.
登录
查看更多内容
影响因子：
9.9
作者：
Araki M;Matsuoka T;Miyamoto K;Kusunoki S;Okamoto T;Murata M;Miyake S;Aranami T;Yamamura T
通讯作者：
Yamamura T
影响因子：
11.2
作者：
Flanagan EP;Cabre P;Weinshenker BG;Sauver JS;Jacobson DJ;Majed M;Lennon VA;Lucchinetti CF;McKeon A;Matiello M;Kale N;Wingerchuk DM;Mandrekar J;Sagen JA;Fryer JP;Robinson AB;Pittock SJ
通讯作者：
Pittock SJ
影响因子：
4.4
作者：
Ajmera, Mayank R.;Boscoe, Audra;Levy, Michael
通讯作者：
Levy, Michael
影响因子：
2.5
作者：
Badaut, J;Verbavatz, JM;Lasbennes, F
通讯作者：
Lasbennes, F
b淋巴细胞神经霉炎。
DOI：
10.1212/nxi.0000000000000104
发表时间：
2015-06
期刊：
Neurology(R) neuroimmunology & neuroinflammation
影响因子：
--
作者：
Bennett JL;O'Connor KC;Bar-Or A;Zamvil SS;Hemmer B;Tedder TF;von Büdingen HC;Stuve O;Yeaman MR;Smith TJ;Stadelmann C
通讯作者：
Stadelmann C